| Autor: |
Athyros VG; Department of Internal Medicine, Second Propedeutic Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece., Elisaf MS, Alexandrides T, Achimastos A, Ganotakis E, Bilianou E, Karagiannis A, Liberopoulos EN, Tziomalos K, Mikhailidis DP |
| Jazyk: |
angličtina |
| Zdroj: |
Angiology [Angiology] 2012 Jul; Vol. 63 (5), pp. 358-66. Date of Electronic Publication: 2011 Oct 17. |
| DOI: |
10.1177/0003319711421341 |
| Abstrakt: |
This post hoc analysis of the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) study assesses the 3½ year incidence of new-onset diabetes (NOD) and related cardiovascular disease (CVD) events in patients with metabolic syndrome (MetS), after multifactorial (lifestyle and drug, including atorvastatin) intervention. Patients were randomized to group A (low-density lipoprotein cholesterol [LDL-C] target < 100 mg/dL) and group B (< 130 mg/dL). The incidence of NOD during the 42-month follow-up was very low, 0.83 to 1.00/100 patient-years in patients with MetS and MetS with impaired fasting glucose, respectively. Older age, increased waist circumference, and persistent MetS were determinants of NOD. One CVD nonfatal event occurred in the 28 patients with NOD. Our findings suggest that treating the characteristics of MetS is achievable and beneficial. New-onset diabetes incidence and CVD events were negligible and not different from what is expected in the general population. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
